Login to Your Account

'Dramatic Change' Coming

Antisoma Shares Tank 64% as AML Drug Fails in Phase III

By Nuala Moran

Wednesday, February 2, 2011
LONDON – Antisoma plc has taken a double hit with the failure of its only two clinical programs, as the lead product AS1413 failed in a pivotal Phase III trial in secondary acute myeloid leukemia (AML) and a Phase IIb trial of AS1411 in AML was halted after an interim analysis. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription